- 中国科学论文统计源期刊
- 中国科技核心期刊
- 美国化学文摘(CA)来源期刊
- 日本科学技术振兴机构数据库(JST)
临床输血与检验 ›› 2023, Vol. 25 ›› Issue (2): 170-179.DOI: 10.3969/j.issn.1671-2587.2023.02.003
黄蓉, 张宁洁, 郝珂, 郭天虹, 黄雪原, 谷兰, 傅云峰, 黄远帅, 王勇军, 陈秉宇, 周岚, 桂嵘
收稿日期:2023-01-11
发布日期:2023-04-25
通讯作者:
黄远帅,研究员,主要从事非编码RNA与肿瘤方面研究,（E-mail）hys@live.cn。作者简介:黄蓉,主要从事输血相容检测方面研究,（E-mail）ronghuang1989@csu.edu.cn。基金资助:
Received:2023-01-11
Published:2023-04-25
中图分类号:
黄蓉, 张宁洁, 郝珂, 郭天虹, 黄雪原, 谷兰, 傅云峰, 黄远帅, 王勇军, 陈秉宇, 周岚, 桂嵘. 从《AABB技术手册》（18版-20版）看国际输血技术新走向*[J]. 临床输血与检验, 2023, 25(2): 170-179.
| [1] Mark K Fung.Cohn.AABB Technical Manual(18th edition)[M].Bethesda, MD:AABB Press,2018. [2] Mark K Fung.Cohn.AABB Technical Manual(19th edition)[M].Bethesda, MD:AABB Press,2019. [3] Claudia S.Cohn.AABB Technical Manual(20th edition)[M].Bethesda, MD:AABB Press,2020. [4] Food and Drug Administration.Guidance for industry: Revised recommendations for reducing the risk of Zika virus transmission by blood and blood components[EB/OL].(2018-07).https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/blood-guidances. [5] Eder AF.Donor reentry.In: Eder AF, Goldman M, eds.Screening blood donors with the donor history questionnaire[M].Bethesda, MD:AABB Press, 2019:209-47. [6] International Society of Blood Transfusion.Red Cell Immunogenetics and Blood Group Terminology (working group)[EB/OL].(2022-11-20).https://www.isbtweb.org/isbt-working-parties/rcibgt.html. [7] YOUNG P P,COTTON B A,GOODNOUGH L T.Massive transfusion protocols for patients with substantial hemorrhage[J].Transfus Med Rev,2011,25(4):293-303. [8] HENDRICKSON J E,SHAZ B H,PEREIRA G,et al.Implementation of a pediatric trauma massive transfusion protocol:one institution’s experience[J].Transfusion,2012,52(6):1228-1236. [9] STANSBURY L G,DUTTON R P,STEIN D M,et al.Controversy in trauma resuscitation:do ratios of plasma to red blood cells matter?[J].Transfus Med Rev,2009,23(4):255-265. [10] CALLUM J L,NASCIMENTO B,TIEN H,et al.Editorial:“formula-driven” versus “lab-driven” massive transfusion protocols:At a state of clinical equipoise[J].Transfus Med Rev,2009,23(4):247-254. [11] HOLCOMB J B,DEL JUNCO D J,FOX E E,et al.The prospective,observational,multicenter,major trauma tran-sfusion (PROMMTT) study:comparative effectiveness of a time-varying treatment with competing risks[J].JAMA Surg,2013,148(2):127-136. [12] PAULL B.Transfusion of plasma,platelets,and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma:the PROPPR randomized clinical trial[J].J Emerg Med,2015,49(1):122. [13] SPERRY J L,GUYETTE F X,BROWN J B,et al.Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock[J].N Engl J Med,2018,379(4):315-326. [14] DZIK W S,ZIMAN A,COHN C,et al.Survival after ultramassive transfusion:a review of 1360 cases[J].Transfusion,2016,56(3):558-563. [15] JOHNSON D J,SCOTT A V,BARODKA V M,et al.Morbidity and mortality after high-dose transfusion[J].Anesthesiology,2016,124(2):387-395. [16] ROSSAINT R,BOUILLON B,CERNY V,et al.The European guideline on management of major bleeding and coagulopathy following trauma:fourth edition[J].Crit Care,2016,20:100. [17] CHANDLER M H,ROBERTS M,SAWYER M,et al.The US military experience with fresh whole blood during the conflicts in Iraq and Afghanistan[J].Semin Cardiothorac Vasc Anesth,2012,16(3):153-159. [18] CAP A P,BECKETT A,BENOV A,et al.Whole blood transfusion[J].Mil Med,2018,183(suppl_2):44-51. [19] YAZER M H,CAP A P,SPINELLA P C,et al.How do I implement a whole blood program for massively bleeding patients?[J].Transfusion,2018,58(3):622-628. [20] YAZER M H,SPINELLA P C.The use of low-titer group O whole blood for the resuscitation of civilian trauma patients in 2018[J].Transfusion,2018,58(11):2744-2746. [21] SEHEULT J N,BAHR M,ANTO V,et al.Safety profile of uncrossmatched,cold-stored,low-titer,group O+ whole blood in civilian trauma patients[J].Transfusion,2018,58(10):2280-2288. [22] STUBBS J R,TRAN S A,EMERY R L,et al.Cold platelets for trauma-associated bleeding:regulatory approval,accreditation approval,and practice implementation-just the tip of the iceberg[J].Transfusion,2017,57(12):2836-2844. [23] SEHEULT J N,ANTO V,ALARCON L H,et al.Clinical outcomes among low-titer group O whole blood recipients compared to recipients of conventional components in civilian trauma resuscitation[J].Transfusion,2018,58(8):1838-1845. [24] GAMMON R, ed.Standards for blood banks and transfusion services.32nd ed[M].Bethesda, MD: AABB, 2020. [25] CURLEY A,STANWORTH S J,WILLOUGHBY K,et al.Randomized trial of platelet-transfusion thresholds in neonates[J].N Engl J Med,2019,380(3):242-251. [26] SOLA-VISNER M C.Platelet transfusions in neonates - less is more[J].N Engl J Med,2019,380(3):287-288. [27] MONAGLE P,BARNES C,IGNJATOVIC V,et al.Developmental haemostasis.Impact for clinical haemostasis laboratories[J].Thromb Haemost,2006,95(2):362-372. [28] COWMAN J,QUINN N,GEOGHEGAN S,et al.Dynamic platelet function on von Willebrand factor is different in preterm neonates and full-term neonates:changes in neonatal platelet function[J].J Thromb Haemost,2016,14(10):2027-2035. [29] HOGLE L F,DAS A.The social production of evidence:regenerative medicine and the 21st Century Cures Act[J].Regen Med,2017,12(6):581-586. [30] ATKINS J W,WEST K,KASOW K A.Current and future cell therapy standards and guidelines[J].Oncol Clin N Am,2019,33(5):839-855. [31] GOLCHIN A,FARAHANY T Z.Biological products:cellular therapy and FDA approved products[J].Stem Cell Rev Rep,2019,15(2):166-175. [32] EL-HAKIM EL-KADIRY A,RAFEI M,SHAMMAA R.Cell therapy:types,regulation,and clinical benefits[J].Front Med,2021,8:756029. [33] ZHANG X M,ZHU L L,ZHANG H,et al.CAR-T cell therapy in hematological malignancies:current opportunities and challenges[J].Front Immunol,2022,13:927153. [34] NEELAPU S S,LOCKE F L,BARTLETT N L,et al.Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma[J].N Engl J Med,2017,377(26):2531-2544. [35] ABRAMSON JS.Anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma[J].Transfus Med Rev,2020,34(1):29-33. [36] DAI H R,WU Z Q,JIA H J,et al.Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia[J].J Hematol Oncol,2020,13(1):1-10. [37] WANG M,MUNOZ J,GOY A,et al.KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma[J].N Engl J Med,2020,382(14):1331-1342. [38] SHAH B D,GHOBADI A,OLUWOLE O O,et al.KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia:phase 2 results of the single-arm,open-label,multicentre ZUMA-3 study[J].Lancet,2021,398(10299):491-502. [39] MUNSHI N C,ANDERSON L D Jr,SHAH N,et al.Idecabtagene vicleucel in relapsed and refractory multiple myeloma[J].N Engl J Med,2021,384(8):705-716. [40] ANDERSON L D Jr.Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma[J].Future Oncol,2022,18(3):277-289. [41] RAJE N,BERDEJA J,LIN Y,et al.Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma[J].N Engl J Med,2019,380(18):1726-1737. [42] CORTÉS-HERNÁNDEZ A,ALVAREZ-SALAZAR E K,SOLDEVILA G.Chimeric antigen receptor (CAR) T cell therapy for cancer.challenges and opportunities:an overview[J].Methods Mol Biol,2021,2174:219-244. [43] STERNER R C,STERNER R M.CAR-T cell therapy:current limitations and potential strategies[J].Blood Cancer J,2021,11(4):69. [44] HASLAUER T,GREIL R,ZABORSKY N,et al.CAR T-c ell therapy in hematological malignancies[J].Int J Mol Sci,2021,22(16):8996. [45] HUANG J W,HUANG X B,HUANG J.CAR-T cell therapy for hematological malignancies:limitations and optimization strategies[J].Front Immunol,2022,13:1019115. [46] LIU Q Z,LIU Z P,WAN R X,et al.Clinical strategies for enhancing the efficacy of CAR T-cell therapy for hematological malignancies[J].Cancers,2022,14(18):4452. [47] HOLSTEIN S A,LUNNING M A.CAR T-cell therapy in hematologic malignancies:a voyage in progress[J].Clin Pharmacol Ther,2020,107(1):112-122. [48] MI J Q,XU J,ZHOU J F,et al.CAR T-cell immunotherapy:a powerful weapon for fighting hematological B-cell malignancies[J].Front Med,2021,15(6):783-804. [49] PAN K,FARRUKH H,CHITTEPU V C S R,et al.CAR race to cancer immunotherapy:from CAR T,CAR NK to CAR macrophage therapy[J].J Exp Clin Cancer Res,2022,41(1):1-21. [50] BIEDERSTÄDT A,REZVANI K.Engineering the next generation of CAR-NK immunotherapies[J].Int J Hematol,2021,114(5):554-571. [51] XIE G Z,DONG H,LIANG Y,et al.CAR-NK cells:a promising cellular immunotherapy for cancer[J].eBioMedicine,2020,59:102975. [52] WANG W,JIANG J,WU C,et al.CAR-NK for tumor immunotherapy: clinical transformation and future prospects[J].Cancer Lett,2020,472:175-180. [53] ALBINGER N,HARTMANN J,ULLRICH E.Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany[J].Gene Ther,2021,28(9):513-527. [54] VAHIDIAN F,KHOSROSHAHI L M,AKBARZADEH M,et al.The tricks for fighting against cancer using CAR NK cells:a review[J].Mol Cell Probes,2022,63:101817. [55] LIU E L,MARIN D,BANERJEE P,et al.Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors[J].N Engl J Med,2020,382(6):545-553. [56] WRONA E,BOROWIEC M,POTEMSKI P.CAR-NK cells in the treatment of solid tumors[J].Int J Mol Sci,2021,22(11):5899. [57] CAO B H,LIU M T,HUANG J J,et al.Development of mesothelin-specific CAR NK-92 cells for the treatment of gastric cancer[J].Int J Biol Sci,2021,17(14):3850-3861. [58] HAN J F,CHU J H,KEUNG CHAN W,et al.CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells[J].Sci Rep,2015,5:11483. [59] HU Z W.Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer[J].Sci Rep,2020,10:2815. [60] LEE Y E,JU A N,CHOI H W,et al.Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment[J].J Control Release,2020,326:310-323. [61] CAO B H,LIU M T,WANG L,et al.Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer[J].Biochem Biophys Res Commun,2020,524(1):96-102. [62] AO X,YANG Y,LI W Q,et al.Anti-αFR CAR-engineered NK-92 cells display potent cytotoxicity against αFR-positive ovarian cancer[J].J Immunother,2019,42(8):284-296. [63] CALLUM J L,WATERS J H,SHAZ B H,et al.The AABB recommendations for the Choosing Wisely campaign of the American Board of Internal Medicine[J].Transfusion,2014,54(9):2344-2352. [64] JONES J M,SAPIANO M R P,SAVINKINA A A,et al.Slowing decline in blood collection and transfusion in the United States - 2017[J].Transfusion,2020,60(Suppl 2):S1-S9. [65] AABB.The 2016 AABB Blood Survey Fact Sheet[EB/OL].(2020-03-26)http://www.aabb.org/research/hemovigilance/bloodsurvey/Pages/default.Aspx. [66] DE VRIES R R P,FABER J C.Hemovigilance:An Effective Tool for Improving Transfusion Safety[M].UK:Wiley,2012. [67] CHUNG K W,HARVEY A,BASAVARAJU S V,et al.How is national recipient hemovigilance conducted in the United States?[J].Transfusion,2015,55(4):703-707. [68] MENIS M,ANDERSON S A,FORSHEE R A,et al.Transfusion-related acute lung injury and potential risk factors among the inpatient US elderly as recorded in Medicare claims data,during 2007 through 2011[J].Transfusion,2014,54(9):2182-2193. [69] JOHN P,Nolan,.Suspension array technology:evolution of the flat-array paradigm[J].Trends Biotechnol,2002,20(1):9-12. [70] LANE W J,WESTHOFF C M,UY J M,et al.Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing:proof of principle[J].Transfusion,2016,56(3):743-754. [71] WILLIAM J,Lane,MD,et al.Automated typing of red blood cell and platelet antigens:a whole-genome sequencing study[J].Lancet Haematol,2018,5(6):e241-e251. [72] FICHOU Y,AUDRÉZET M P,GUÉGUEN P,et al.Next-generation sequencing is a credible strategy for blood group genotyping[J].Br J Haematol,2014,167(4):554-562. [73] MCBEAN RS, HYLAND CA, FLOWER RL.Approaches to determination of a full profile of blood group genotypes:single nucleotide variant mapping and massively parallel sequencing[J].Comput Struct Biotechnol J,2014,11(19):147-151. [74] WAGNER F F.RHD PCR of D-negative blood donors[J].Transfus Med Hemother,2013,40(3):172-181. [75] PHAM B N,PEYRARD T,TOURRET S,et al.Anti-HrB and anti-hrb revisited[J].Transfusion,2009,49(11):2400-2405. [76] REID M E,HIPSKY C H,VELLIQUETTE R W,et al.Molecular background of RH in Bastiaan,the RH:-31,-34 index case,and two novel RHD alleles[J].Immunohematology,2012,28(3):97-103. [77] KELLER MA, HORN T, CROWLEY J, et al.Genotype compatibility tables for matching patients and donors for RH variants[J].Transfusion,2013,53(2S): 174A. [78] NAY W.Hyperhemolysis syndrome in sickle cell disease[J].Expert Rev Hematol,2009,2(2):111-115. [79] CHONAT S,QUARMYNE M O,BENNETT C M,et al.Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease[J].Haematologica,2018,103(10):e483-e485. [80] DUMAS G,HABIBI A,ONIMUS T,et al.Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients[J].Blood,2016,127(8):1062-1064. [81] WIN N, SINHA S, LEE E, MILLS W.Treatment with intravenous immunoglobulin and steroids may correct severe Anemia in hyperhemolytic transfusion reactions:case report and literature review[J].Transfus Med Rev,2010,24(1):64-67. [82] PIRENNE F,YAZDANBAKHSH K.How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions[J].Blood,2018,131(25):2773-2781. [83] MEKONTSO DESSAP A,PIRENNE F,RAZAZI K,et al.A diagnostic nomogram for delayed hemolytic transfusion reaction in sickle cell disease[J].Am J Hematol,2016,91(12):1181-1184. [84] HABIBI A,MEKONTSO-DESSAP A,GUILLAUD C,et al.Delayed hemolytic transfusion reaction in adult sickle-cell disease:presentations,outcomes,and treatments of 99 referral center episodes[J].Am J Hematol,2016,91(10):989-994. [85] VIDLER J B,GARDNER K,AMENYAH K,et al.Delayed haemolytic transfusion reaction in adults with sickle cell disease:a 5-year experience[J].Br J Haematol,2015,169(5):746-753. [86] PADMANABHAN A,CONNELLY-SMITH L,AQUI N,et al.Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American society for apheresis:the eighth special issue[J].J Clin Apher,2019,34(3):171-354. [87] BOADA M,LÓPEZ O L,OLAZARÁN J,et al.A randomized,controlled clinical trial of plasma exchange with albumin replacement for Alzheimer’s disease:primary results of the AMBAR Study[J].Alzheimers Dement,2020,16(10):1412-1425. [88] NAKATSUJI Y.Therapeutic apheresis in neurological disorders[J].Brain Nerve,2021,73(5):425-430. [89] SZCZEPIORKOWSKI Z M.Indications for therapeutic apheresis in hematological disorders[J].Semin Hematol,2020,57(2):57-64. [90] CHEN Y Y,SUN X,HUANG W,et al.Therapeutic apheresis in kidney diseases:an updated review[J].Ren Fail,2022,44(1):842-857. [91] PANDEY P,SETYA D,SINHA V,et al.Therapeutic apheresis in ABO-incompatible kidney and liver transplantation:a single-center experience of 50 patients[J].Ther Apher Dial,2021,25(1):103-117. [92] DUAN W,ZHOU H,DONG X,et al.Application of lymphoplasmapheresis in the treatment of severe myasthenia gravis[J].Front Neurol,2022,13:1018509. [93] OUYANG S,YIN W F,ZENG Q M,et al.Lymphoplasma exchange improves myasthenia gravis exacerbations:a retrospective study in a Chinese center[J].Front Immunol,2022,13:757841. [94] WANG B,LI J,XIE H F,et al.Striking case of Febrile ulceronecrotic Mucha-Habermann disease responding to lymphoplasmapheresis and methotrexate[J].J Dermatol,2020,47(12):e430-e431. [95] ZHANG Z M,YUAN X,JIANG Y J,et al.Effectiveness of lymphoplasmapheresis compared with therapeutic plasma exchange for thrombotic thrombocytopenic purpura:a retrospective evaluation[J].Hematology,2022,27(1):167-172. [96] ZHANG Z,SHEN Y,SHU X,et al.Successful whole-blood exchange transfusion in a patient with paroxysmal nocturnal hemoglobinuria:a case report and literature review[J].J Int Med Res,2019,47(9):4562-4567. [97] Food and Drug Administration.Guidance for Industry: Revised recommendations to reduce the risk of transfusion-transmitted malaria[EB/OL].(2020-04).https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-reduce-risktransfusion-transmitted-malaria. [98] Food and Drug Administration.Guidance for Industry: Revised recommendations to reduce the risk of human immunodeficiency virus transmission by blood and blood products[EB/OL].(2020-04).https://www.fda.gov/regulatory-information/search-fda-guidance-documents/revised-recommendations-reducing-risk-humanimmunodeficiency-virus-transmission-bloodand-blood. [99] CID J,ESCOLAR G,GALAN A N,et al.In vitro evaluation of the hemostatic effectiveness of cryopreserved platelets[J].Transfusion,2016,56(3):580-586. [100] VALERI C R,RAGNO G,KHURI S.Freezing human platelets with 6 percent dimethyl sulfoxide with removal of the supernatant solution before freezing and storage at-80 degrees C without postthaw processing[J].Transfusion,2005,45(12):1890-1898. [101] NAIR P M,PIDCOKE H F,CAP A P,et al.Effect of cold storage on shear-induced platelet aggregation and clot strength[J].J Trauma Acute Care Surg,2014,77(3 Suppl 2):S88-S93. |
| [1] | 邓桂花, 龙馨妍, 孙亚纯, 王雷萍, 张传国, 孟庆宝. 智慧型输血医学科的建设[J]. 临床输血与检验, 2023, 25(2): 185-189. |
| [2] | 葛霜, 汪德清. 2021—2022年度输血医学研究进展*[J]. 临床输血与检验, 2023, 25(2): 276-281. |
| [3] | 李杨, 戎瑞明. 细胞治疗在肾脏移植中的应用前景*[J]. 临床输血与检验, 2022, 24(6): 687-692. |
| [4] | 中国输血协会临床输血学专业委员会. 非心脏外科围手术期患者血液管理专家共识（2022版）[J]. 临床输血与检验, 2022, 24(5): 545-553. |
| [5] | 胡兴斌. 我国当前医学教育模式下输血医学研究生培养的思考与实践[J]. 临床输血与检验, 2022, 24(5): 554-559. |
| [6] | 陈学军, 徐军, 尹明伟, 周超, 沈月芳. 英格兰临床和实验室输血五年计划：输血2024的要点及启示[J]. 临床输血与检验, 2022, 24(5): 560-564. |
| [7] | 刘峰, 周吉成, 刘榕孜, 谭彬宾, 谢春梅. 国内部分高等医药院校开设输血医学课程的现状分析及建议[J]. 临床输血与检验, 2022, 24(4): 501-506. |
| [8] | 于洋. 基于中国输血大讲堂的网络在线继续教育模式探索与实践[J]. 临床输血与检验, 2022, 24(1): 104-108. |
| [9] | 王文静, 赵儒, 王琪, 陈利达, 陈文慧, 芦宏凯. 肺移植患者血液管理研究进展*[J]. 临床输血与检验, 2021, 23(3): 404-408. |
| [10] | 吴建君, 史荣辉, 赵树铭. 临床输血医师工作内容探讨[J]. 临床输血与检验, 2021, 23(1): 17-19. |
| [11] | 周文玲, 杨融辉, 金晶纯, 肇硕, 郝一文. 围手术期患者血液管理对手术用血量影响作用的分析[J]. 临床输血与检验, 2020, 22(5): 501-506. |
| [12] | 崔颖, 陈扬, 王文婷, 魏华, 穆士杰. PBL结合LBL教学模式在临床输血实习带教中的应用与体会[J]. 临床输血与检验, 2020, 22(1): 36-38. |
| [13] | 吴雪萍, 杨文勇, 陆兴热, 高仕萍, 王孝梅. 输血科实习生带教体系的建立与应用研究[J]. 临床输血与检验, 2019, 21(5): 544-547. |
| [14] | 杨晓亮, 兰炯采, 胡雪, 王静, 李青, 余泽波. 中医药促进红细胞与血小板再生在输血医学中的应用与研究进展[J]. 临床输血与检验, 2019, 21(3): 252-255. |
| [15] | 孙洁,陆韬宏,王春燕,刘渊,周蓉,孟妍. 患者血液管理在临床输血实践中的应用*[J]. 临床输血与检验, 2018, 20(4): 337-339. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
